Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

Virology. 2014 Mar;452-453:32-41. doi: 10.1016/j.virol.2014.01.002. Epub 2014 Jan 28.

Abstract

The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.

Keywords: Coronavirus; Measles vaccine; Severe acute respiratory syndrome; Spike glycoprotein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Genetic Vectors / genetics
  • Genetic Vectors / immunology
  • Humans
  • Male
  • Measles Vaccine / genetics
  • Measles Vaccine / immunology
  • Measles virus / genetics*
  • Measles virus / immunology
  • Mice
  • SARS Virus / genetics
  • SARS Virus / immunology
  • SARS Virus / physiology*
  • Severe Acute Respiratory Syndrome / immunology
  • Severe Acute Respiratory Syndrome / prevention & control*
  • Severe Acute Respiratory Syndrome / virology
  • Spike Glycoprotein, Coronavirus / administration & dosage
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology*
  • Th1 Cells / immunology
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Measles Vaccine
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike glycoprotein, SARS-CoV